Overview

Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency

Status:
Recruiting
Trial end date:
2022-07-11
Target enrollment:
Participant gender:
Summary
This study is a double-blind, double-dummy, two-way cross-over, randomised, Phase II study to be conducted at approximately 6 investigational sites in 2 countries. The study will compare the efficacy, safety and tolerability of twice daily Chronocort, a modified-release hydrocortisone, with once daily Plenadren, a modified-release hydrocortisone, over a treatment period of up to 2 months in participants aged 18 years and over, diagnosed with primary Adrenal Insufficiency (AI).
Phase:
Phase 2
Details
Lead Sponsor:
Diurnal Limited
Treatments:
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate